Foresite Capital Management III’s Blueprint Medicines BPMC Stock Holding History

Foresite Capital Management III’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-249,598	Closed	-$19.5M	–	11
2020 Q2	$19.5M	Buy	249,598 +79,698	+47%	+$5.39M	17.31%	2
2020 Q1	$9.94M	Buy	+169,900	New	+$10.9M	15.82%	3
2019 Q4	–	Sell	-559,381	Closed	-$41.1M	–	11
2019 Q3	$41.1M	Buy	559,381 +91,699	+20%	+$7.93M	15.69%	3
2019 Q2	$44.1M	Hold	467,682	–	–	14.47%	2
2019 Q1	$37.4M	Hold	467,682	–	–	9.75%	4
2018 Q4	$25.2M	Buy	467,682 +267,682	+134%	+$16.3M	8.28%	4
2018 Q3	$15.6M	Sell	200,000 -50,000	-20%	-$3.48M	3.44%	8
2018 Q2	$15.9M	Sell	250,000 -150,000	-38%	-$11.9M	3.42%	9
2018 Q1	$36.7M	Hold	400,000	–	–	7.99%	6
2017 Q4	$30.2M	Sell	400,000 -67,682	-14%	-$4.76M	8.46%	4
2017 Q3	$32.6M	Buy	467,682 +7,682	+2%	+$411K	8.97%	4
2017 Q2	$23.3M	Buy	460,000 +199,600	+77%	+$8.48M	7.61%	4
2017 Q1	$10.4M	Sell	260,400 -39,600	-13%	-$1.42M	4%	8
2016 Q4	$8.41M	Buy	+300,000	New	+$9.04M	3.66%	8

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Foresite Capital Management III's BPMC Position: Q3 2020 in Review

Foresite Capital Management III sold out of Blueprint Medicines (BPMC) in Q3 2020, closing a stake of 249,598 shares — an estimated $19.5M sold.

Foresite Capital Management III first reported a position in BPMC in Q4 2016 and held it in 14 quarters. The position peaked at $44.1M in Q2 2019. 237 funds tracked by Wall St. Rank hold BPMC as of Q3 2020.

Foresite Capital Management III reported no remaining Blueprint Medicines position as of Q3 2020 after selling out during the quarter.
Foresite Capital Management III sold 249,598 Blueprint Medicines shares in Q3 2020, an estimated $19.5M.
Foresite Capital Management III first reported a position in Blueprint Medicines in Q4 2016 and held it in 14 quarters.
Foresite Capital Management III's Blueprint Medicines position peaked at $44.1M in Q2 2019.
237 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2020.

Based on Foresite Capital Management III's 13F filing for Q3 2020, filed 13 Nov 2020.